Proactive news headlines: Quadrise Fuels International PLC, Tiziana Life Sciences

() shares soared in Tuesday morning’s deals as it confirmed a partnership aimed at heavy and paraffinic oil deposits in Utah is advancing. The chemical technology firm in February signed a memorandum of understanding to evaluate a proposed opportunity being pursued by Greenfield Energy LLC, a joint venture company for () and Valkor Technologies – which previously had a technology licensing agreement with Quadrise. Quadrise today announced that the partnership with Greenfield has entered Phase 1 which will see a commercial trial, using its MSAR technology – which creates an emulsified synthetic heavy fuel oil – at the Petroteq Oil Sands Plant (POSP) at the Asphalt Ridge Facility in Utah. Phase 1 has a commercial value of US$150,000 to Quadrise, the company noted. It will initially see proof of concept work at the Quadrise Research Facility using oil samples supplied by Greenfield. 

() (NASDAQ:TLS) has announced that the US Patent and Trademark Office (USPTO) has granted a patent on use and methods of treatment of Crohn’s disease with Foralumab, its proprietary fully human monoclonal antibody, and all other anti-CD3 monoclonal antibodies (mAb). The biotechnology company, which is focused on innovative therapeutics for oncology, inflammation and infectious diseases, noted that the CD3 (cluster of differentiation 3) is a protein complex on T-cells, which is important for the regulation of the immune system. It said the patent will be published by the USPTO on September 1, 2020, as Patent No.10,759,858.  

[email protected] Capital PLC () has revealed that Orchestra Group, which is owned by its CEO Alessandro Zamboni has acquired 1,630,000,000 ordinary shares of 0.002p each in the capital of the company at 0.6756p per share from Ceresio SIM S.p.A.. The share purchase increases Orchestra Group’s holding in [email protected] to 23.96% of its share capital, up from 18.98% previously.

() has highlighted continued growth in its digital media business, saying the business arm is expected to generate £2mln in revenues for the financial year ending June 30, 2021. The esports events group said the digital media arm was one of its fastest-growing revenue streams, having delivered close to £200,000 through on-site advertising by the end of July after implementing a partnership with advertising group Venatus in mid-April. Gfinity also said the business line has been selected to deliver a “growing number of repeat advertising campaigns for high-profile publishers”, with a “strong pipeline” of direct campaigns already secured and running in August.

OKYO Pharma Ltd () said it plans to dual-list its shares on the US Nasdaq market as it raised another £1.4mln and published full-year results overnight. The London-listed company, which is developing novel molecules to treat inflammatory dry eye diseases and chronic pain, issued another round of convertible loan notes (CLNs) on the same terms as those issued last month. This takes its fundraising to £5.4mln since the end of March as it gears up to begin clinical trials for dry eye and exploring additional pain-related peptides in the coming year. OKYO said it now intends to begin the process to obtain a dual listing of its existing shares on Nasdaq, subject to the required regulatory approvals.

(), the largest specialist fishing tackle and equipment retailer in the UK, said it saw strong pent-up sales demand when its stores reopened following closures for the coronavirus (COVID-19) pandemic. All of the group’s UK stores are now open for business again and saw year-on-year like-for-like (LFL) sales growth of 75% between June 15, 2020, and the end of July. Sales across all channels in the same period were up 95% on the corresponding period of 2019, despite all of its bricks and mortar stores being closed between March 24 and June 14. Revenue in the first half of 2020 was up 21% to £32.1mln from £26.5mln in the first half of 2019, with online sales –…